Abstracts tagged "Wegener’s granulomatosis and rituximab"

Abstract Number: 1654 • ACR/ARHP Annual Meeting 2012
Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial
Eli Miloslavsky¹, Ulrich Specks², John H. Stone³ and RAVE/ITN Research Group⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Bethesda, MD
Primary Endpoint Failure in the Rituximab in ANCA-associated Vasculitis TrialBackground/Purpose: The RAVE trial demonstrated that rituximab (RTX) is non-inferior to cyclophosphamide (CYC) for remission induction…
Abstract Number: 1544 • ACR/ARHP Annual Meeting 2012
Long-Term Outcome of Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Rituximab
Lama Azar¹, Jason Springer², Meng Xu³, Tiffany M. Clark⁴, Carol A. Langford⁵ and Gary S. Hoffman⁴, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Section of biostatistics, Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ⁴Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ⁵Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH
Background/Purpose: Rituximab (RTX) is an efficacious alternative to cyclophosphamide for treatment of granulomatosis with polyangiitis (GPA). However, relapses have been observed, long-term efficacy is not…